IFN-β liquid formulations

Details IFN-β liquid formulations IFN-β liquid formulations

2004-07-16

2008-08-05

Landsman, Robert (Department: 1647)

Drug, bio-affecting and body treating compositions

Lymphokine

Interferon

C215S014000, C215S049000, C530S351000

Reexamination Certificate

active

07407651

ABSTRACT:
Interferon-beta liquid formulations stabilized with a polyol, a non-reducing sugar or a amino acid. In particular, the formulations are stabilized with a polyol, such as mannitol. The formulations, preferably, furthermore comprise a buffer, such as acetate buffer, at a pH comprised between 3.0 and 4.0 and human albumin at a minimum quantity. The interferon-beta is preferably recombinant.

REFERENCES:
patent: 4465622 (1984-08-01), Nobuhara et al.
patent: 4647454 (1987-03-01), Cymbalista et al.
patent: 4675184 (1987-06-01), Hasegawa et al.
patent: 4724232 (1988-02-01), Rideout et al.
patent: 5004605 (1991-04-01), Hershenson et al.
patent: 5183746 (1993-02-01), Shaked et al.
patent: 5643566 (1997-07-01), Hanisch et al.
patent: 089245 (1983-08-01), None
patent: 270799 (1988-06-01), None
patent: WO 89/02750 (1989-04-01), None
patent: PCT 89/04177 (1989-05-01), None

Affiliated with

Also associated with

Rating

IFN-β liquid formulations does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with IFN-β liquid formulations, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and IFN-β liquid formulations will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3995055